Farkas Charles 4

What Happened Charles Farkas, a director of CONMED Corporation (CNMD), was granted 5,772 restricted stock units (RSUs) on 2026-06-01 (reported on a Form 4 filed 2026-06-03). The filing also reports exercise/conversion of 668 derivative shares on 2026-06-02 (an acquisition entry) and a matching disposition of 668 shares the same day. All reported transactions show $0.00 per share and $0 total value in the filing.

Key Details

• Transactions reported:
  • 2026-06-01 — Grant/Award (code A): 5,772 RSUs @ $0.00 (acquired).
  • 2026-06-02 — Exercise/Conversion (code M): 668 shares @ $0.00 (acquired).
  • 2026-06-02 — Exercise/Conversion (code M): 668 shares @ $0.00 (disposed).
• Footnotes: Each RSU represents a contingent right to one share under CONMED’s 2025 Long-Term Incentive Plan; RSUs generally vest 100% after one year (per footnotes F1/F2).
• Filing: Form 4 filed 2026-06-03 for transactions dated 2026-06-01 and 2026-06-02 — filing appears timely based on provided dates.
• Shares owned after the transactions are not specified in the provided excerpt.

Context

• The 5,772-item entry is an RSU award (an acquisition of a contingent right to shares) and will convert to common stock only upon vesting per the plan terms.
• The filing shows an equal acquisition and disposition of 668 shares on the same day; that pattern frequently reflects an immediate sale following conversion/vesting or tax-related withholding, but the Form 4 here does not state the reason.
• Awards and conversions can be routine compensation actions and do not by themselves signal management’s view of the company’s stock price.